Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review by Kryklyva, V. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/206713
 
 
 
Please be advised that this information was generated on 2019-12-31 and may be subject to
change.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=kcbt20
Cancer Biology & Therapy
ISSN: 1538-4047 (Print) 1555-8576 (Online) Journal homepage: https://www.tandfonline.com/loi/kcbt20
Pancreatic acinar cell carcinoma is associated
with BRCA2 germline mutations: a case report and
literature review
Valentyna Kryklyva, Nadia Haj Mohammad, Folkert H.M. Morsink, Marjolijn
J.L. Ligtenberg, G. Johan A. Offerhaus, Iris D. Nagtegaal, Wendy W.J. de Leng
& Lodewijk A.A. Brosens
To cite this article: Valentyna Kryklyva, Nadia Haj Mohammad, Folkert H.M. Morsink,
Marjolijn J.L. Ligtenberg, G. Johan A. Offerhaus, Iris D. Nagtegaal, Wendy W.J. de Leng &
Lodewijk A.A. Brosens (2019): Pancreatic acinar cell carcinoma is associated with BRCA2
germline mutations: a case report and literature review, Cancer Biology & Therapy, DOI:
10.1080/15384047.2019.1595274
To link to this article:  https://doi.org/10.1080/15384047.2019.1595274
© 2019 The Author(s). Published with
license by Taylor & Francis Group, LLC.
Published online: 19 Apr 2019.
Submit your article to this journal 
Article views: 321
View Crossmark data
Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case
report and literature review
Valentyna Kryklyvaa, Nadia Haj Mohammadb, Folkert H.M. Morsinkc, Marjolijn J.L. Ligtenberga,d, G. Johan A. Offerhausc,
Iris D. Nagtegaala, Wendy W.J. de Lengc, and Lodewijk A.A. Brosensa,c
aDepartment of Pathology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands;
bDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; cDepartment of Pathology,
University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; dDepartment of Human Genetics, Radboud Institute for Molecular
Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
ABSTRACT
Acinar cell carcinoma (ACC) is a rare pancreatic neoplasm with dismal prognosis. Insights into the
molecular basis of ACC can pave the way for the application of more effective, personalized therapies
and detection of patients with hereditary predisposition.
Molecular analysis revealed a germline BRCA2 (and CHEK2) mutation in a patient with a rare
pancreatic ACC with extensive intraductal growth. Somatic loss of the wild-type BRCA2 allele in the
tumor indicated the causal relationship of ACC with the germline defect. A thorough literature review
identified another nine ACCs associated with germline BRCA2 mutation and two ACCs associated with
germline BRCA1 mutation, resulting in a prevalence of BRCA1/2 germline mutations in almost 7% of
ACCs. Moreover, somatic BRCA1/2 alterations are reported in 16% of sporadic ACCs. Overall, about one
fifth (22%) of all pancreatic ACCs exhibit BRCA1/2 deficiency.
This study underscores the important role of BRCA1/2 mutations in pancreatic ACC. All ACC patients
should undergo genetic testing for BRCA1/2 mutations to identify carriers of pathogenic variants. This
will allow to select patients that can benefit from targeted therapies directed against BRCA1/2-deficient
tumors and is also crucial as a referral to genetic screening for the relatives of affected individuals
carrying germline BRCA1/2 alterations.
Abbreviations: ACC: acinar cell carcinoma; HBOC: Hereditary Breast and Ovarian Cancer; LOH: loss of
heterozygosity; PARP: poly (ADP-ribose) polymerase; PDAC: pancreatic ductal adenocarcinoma; PP:
pancreatic panniculitis; SD: standard deviation; WES: whole-exome sequencing.
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Introduction
Acinar cell carcinoma (ACC) is a rare pancreatic malignancy
with poor prognosis accounting for <2% of all pancreatic
tumors in adults and for about 15% in pediatric cases.1–3 At
time of diagnosis, 50–60% of patients have distant metastasis
and an advanced stage of disease leading to low survival rate
and overall dismal prognosis.1,4 Nonetheless, 5-year survival
of ACC patients is 45% which is higher compared to only 7%
in conventional pancreatic ductal adenocarcinoma (PDAC).1
About 15% of ACC patients present with pancreatic pannicu-
litis (PP), characterized by subcutaneous fat necrosis.1,4
The genomic landscape of ACC is distinct from other
pancreatic tumors.3,5–8 Typical genetic alterations observed
in PDAC are normally not detected in ACC or occur rarely,
i.e., mutations in KRAS (~2% ACCs vs. >90% PDACs), TP53
(9–23% vs. 75%), CDKN2A (14% vs. 90%), SMAD4 (14–19%
vs. 55%).6,9 Rare mutations in BRAF, GNAS and JAK1 and
fusions in BRAF and RAF (detected in 23% of ACCs) indicate
that a minority of ACCs can evolve due to driver events in
oncogenes.6,9 Recent sequencing studies revealed that ACCs
carry on average about 65 non-synonymous somatic muta-
tions per tumor. Importantly, ACC appears to have few
recurrent gene mutations since there were no genes mutated
in more than 30% of ACC.6 Twenty to 25% of ACCs harbor
abnormalities in Wnt/β-catenin pathway, including mutations
in APC and CTNNB1 genes.8 The lack of highly recurrent
mutations suggests that other genetic mechanisms drive
tumor progression in ACC.3 Indeed, extensive chromosomal
instability appears to be a defining feature of ACC distin-
guishing it from other pancreatic malignancies, potentially
contributing to disease severity, progression and chemother-
apy resistance.2,3,6,7,10 Amongst others loss of heterozygosity
(LOH) of chromosomes 11p (~50% of ACCs), 17p (TP53
locus; 39%), and 18q (SMAD4 locus; 57%) is frequently
detected.6–8 Importantly, despite the genetic heterogeneity,
approximately 44% of ACCs harbor potentially targetable
genetic abnormalities in DNA repair by homologous recom-
bination (BRCA1/2, PALB2, BRIP1, BAP1, and ATM), JAK-
STAT signaling cascade (JAK1), MAPK pathway (BRAF), and
cell cycle control (CDKN2A, ID3, and APC).3,6,9
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Although the association of BRCA1/2 mutations with
familial and sporadic PDAC is established,11 there is only
limited data on the role of BRCA1/2 genes in ACC.2,7 Since
BRCA1/2 mutations are targets for therapy with platinum-
based chemotherapeutics and poly (ADP-ribose) polymer-
ase (PARP) inhibitors,12 it is important to determine the
role of BRCA1/2 deficiency in the pathogenesis of pancrea-
tic ACC. In addition, recognition of ACC as a phenotypic
expression of a germline BRCA1/2 mutations is crucial for
screening of patients and their families.
Here we describe a rare case of an ACC in a patient with
a germline BRCA2 mutation, provide molecular evidence for
a causal link between BRCA2 germline mutation and ACC,
and review the literature on the role of germline and somatic
BRCA1/2 mutations in ACC.
Case report
A 52-year-old man carrying a germline BRCA2 mutation pre-
sented with steatorrhea, abdominal pain and weight loss. His
mother died at age 41 from breast cancer, and his sister was
diagnosed with high grade serous ovarian adenocarcinoma.
Abdominal CT scan revealed a tumor in the body and tail of
the pancreas, suggestive of adenocarcinoma arising from the
main-duct intraductal papillary mucinous neoplasm (IPMN).
Endoscopic ultrasound with fine-needle aspiration cytology was
performed and showed cytology consistent with ACC (Figure 1
(a,b)). The patient underwent total pancreatectomy and histo-
logical examination confirmed an ACC with extensive intra-
ductal spread (Figure 1(c,d)).13 One out of 11 lymph nodes
showed metastasis. All surgical margins were free of tumor.
Figure 1. Fine needle aspiration cytology showed a highly cellular specimen consisting of a monotonous population of single cells and clusters of cells with
a moderate amount of basophilic cytoplasm (a). The nuclei are round to oval with moderate anisonucleosis and a single prominent nucleolus (arrows) (b).
Histologically the tumor showed extensive intraductal growth in the main pancreatic duct (PD) and side branches (SB) (c). The tumor was composed of uniform cells
with granular cytoplasm and nucleoli with a single prominent nucleolus (arrows), forming small lumina (d). Immunohistochemically, the tumor cells were strongly
positive for BCL10 (e) and negative for Chromogranin A (f). Note the opposite staining patterns in the adjacent islets of Langerhans (arrows). PD, pancreatic duct; SB,
side branch of pancreatic duct.
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Since the histopathological examination did not show ade-
nocarcinoma, no adjuvant chemotherapy with gemcitabine
was indicated. The patient recovered well, but six months
postoperatively, multiple metastases appeared involving the
lung, liver, peritoneum, and skin. Chemotherapy with oxali-
platin, 85 mg/m2 of body-surface area; irinotecan, 180 mg/m2;
leucovorin, 400 mg/m2; and fluorouracil, 400 mg/m2 given as
a bolus followed by 2400 mg/m2 given as a 46 hours contin-
uous infusion, every 2 weeks (FOLFIRINOX) was initiated.14
The first evaluation CT scan showed partial response of liver
metastases. Dose adjustments were made due to hematologi-
cal toxicity. However, after more than one year of treatment
(24 cycles), the neuropathy was too invalidating to perform
his work and FOLFIRINOX was stopped. Unfortunately, the
patient died three months later because of disease progression.
Materials and methods
Immunohistochemistry
Immunohistochemistry was performed using standard conditions
in the Benchmark Ultra autostainer (Ventana Medical Systems,
Inc. A Member of the Roche Group, Tucson, AZ, USA) with the
following antibodies: Alpha-1-antitrypsin (1:20000; clone zmaat3,
Zymed), β-catenin (1:40; clone 14, Cellmarque), BCL10 (1:400;
clone 331.3, Santa Cruz), Chromogranin A (1:6400; clone
LK2H10, Thermo Fisher Scientific), Cytokeratin 7 (1:6400; clone
OV-TL 12/30, Biogenex), Cytokeratin 19 (1:100; clone B170,
Novocastra), Cytokeratin 20 (1:200; clone Ks20.8, Dako),
SMAD4 (1:800; clone EP6184, Abcam), MLH1 (1:20; clone
G168-15, Pharmingen), MSH2 (1:50; clone G219-1129,
Cellmarque), MSH6 (1:200; clone EPR3945, Abcam), PMS2
(1:25; clone EPR3947, Cellmarque), p53 (1:6000; clone DO-7,
Dako), and Synaptophysin (1:100; clone 27G12, Novocastra).
DNA isolation
Genomic DNA was isolated from paraffin-embedded tissue.
After deparaffinization, DNA was isolated using the Puregene
DNA Isolation kit (Gentra Systems, Minneapolis, MN, USA).
DNA concentrations were measured using the PicoGreen
Double-Stranded DNA Quantitation kit (Molecular Probes,
Leiden, The Netherlands).
DNA sequencing
Next-generation sequencing was performed using the Ion
AmpliSeq Cancer Hotspot Panel v2, which includes 50 cancer-
related genes and which was supplemented with five additional
genes (Table 1), and the Oncomine BRCA Panel which includes
the entire coding region of BRCA1 and BRCA2 (Thermo Fisher
Scientific). Library preparation and sequencing using the Ion
PGM System were performed as described previously.15
Multiplex ligation-dependent probe amplification (MLPA)
MLPA was performed to confirm LOH of BRCA2 using
BRCA2/CHEK2 P045 probemix (MRC Holland, Amsterdam,
The Netherlands) according to manufacturer’s instructions.
Results were normalized on all control probes present in the
kit and normal samples without copy number alterations.
Deletions and duplications were defined as ratios of <0.55
and >1.45, respectively. The assay was performed in duplicate.
Results
Histopathology and immunohistochemistry
Histopathological examination of the tumor confirmed the
diagnosis of pancreatic ACC. The tumor demonstrated strong
positivity for pancreatic acinar cell marker BCL10 (Figure 1(e)).
Cytokeratins 19 and 7 stained positive and Cytokeratin 20 was
negative. Partial expression was observed for Alpha-1-antitryp-
sin. Chromogranin A (Figure 1(f)) and Synaptophysin were
negative. Expression of p53 was wild-type, and β-catenin
showed only membranous localization. No loss of SMAD4 or
any of the mismatch repair proteins (MLH1, MSH2, MSH6,
PMS2) was detected.
Molecular analysis
No mutations were found using the Cancer Hotspot Panel
(Table 1). BRCA sequencing revealed an inactivating BRCA2
mutation (NM_000059.3: c.7974C>G or p.Tyr2658*, VAF 80%
indicating the loss of the wild-type allele), which is considered
pathogenic by ClinVar.16 Sequence analysis of DNA isolated
from a blood sample at clinical genetics showed that this is
a germline mutation. MLPA analysis revealed loss of one
BRCA2 allele in the tumor tissue, further confirming biallelic
inactivation of BRCA2. In addition, somatic LOH of BRCA1was
detected by BRCA sequencing and a germline CHEK2mutation
(c.1100delC or p.Thr367Metfs) was identified by MLPA.
Literature review of pancreatic ACCs associated with
germline BRCA1/2 mutations
Literature review of ACC in patients with a germline BRCA2
mutation identified nine additional cases (Table 2).7,17–21 The
mean age at diagnosis was 62 years (SD: 8.7; range: 50–78),
which is similar to sporadic cases.4 Including the current patient,
seven males (67%) and three females (33%) were identified,
resulting in male-to-female ratio of 2.3:1, corresponding to the
male predominance in sporadic ACC.1,2 All specified BRCA2
mutations were truncating.7,17,21 Noteworthy, in all six cases
Table 1. List of 50 target genes of the Ion AmpliSeq Cancer Hotspot Panel v2
supplemented with five additional genes.
ABL1 CSF1R GNA11 KRAS PTEN
AKT1 CTNNB1 GNAS MDM2 PTPN11
ALK EGFR GNAQ MET RB1
APC ERBB2 HNF1A MLH1 RET
ARAF ERBB4 HRAS MPL SMAD4
ATM EZH2 IDH1 MYD88 SMARCB1
BRAF FBXW7 JAK2 NOTCH1 SMO
CALR FGFR1 JAK3 NPM1 SRC
CDH1 FGFR2 IDH2 NRAS STK11
CDKN2A FGFR3 KDR PDGFRA TP53
CRAF FLT3 KIT PIK3CA VHL
In bold are indicated five additional genes that were added to the 50 target
genes of the Ion AmpliSeq Cancer Hotspot Panel v2.
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with known zygosity, loss of the wild-type BRCA2 allele was
detected.7,17 Three out of 10 patients had a previous personal
history of another BRCA2-associated malignancy, including
breast, ovarian and prostate cancers.17,18,20 In addition, three
patients, including the current, had a family history of BRCA2-
associated malignancies and/or family member(s) harboring
germline BRCA2 mutations.18,19 Two patients presented with
PP as the initial manifestation of ACC.19,20 In addition, literature
search identified two ACC patients with BRCA1 germline
mutation.22–24 Among 46 ACCs tested by germline sequencing
(Furukawa et al.7 (n = 7), Jakel et al.3 (n = 22), Lowery et al.24 (n =
17)), one patient (2.2%) with BRCA124 and two patients (4.3%)
with BRCA27 mutations were detected.
Literature review of somatic BRCA1/2 mutations in
pancreatic ACC
Review of literature detected 12 ACCs with somatic BRCA2
mutations and four – with somatic BRCA1 mutations
(Table 3).6,7,9,25,26 Of note, all four ACCs with somatic
BRCA1 mutations were identified in a single study based on
comprehensive genomic profiling of tumor series consisting
of 44 ACCs,9 whereas 11 out of 12 ACCs containing somatic
BRCA2 mutations were detected in genome sequencing
studies6,7,9 and one additional ACC was described in a case
study and patient-derived animal model.25,26
Among ACCs (n = 94) tested for the presence of somatic
BRCA1/2 alterations with genome sequencing approaches
(Chmielecki et al.9 (n = 44), Jiao et al.6 (n = 21), Furukawa
et al.7 (n = 7), Jakel et al.3 (n = 22)),3,6,7,9 overall 15/94 ACCs
(16%) harbored a somatic mutation in either BRCA1 or
BRCA2. Specifically, 11/94 ACCs (11.7%) contained in total
of 12 somatic BRCA2 mutations, and 4/94 ACCs (4.3%)
exhibited one somatic BRCA1 mutation each. The majority
of BRCA2 mutations were frameshifts introducing
a premature stop codon.7,9 Two somatic BRCA2 variants
were missense mutations leading to the change of correspond-
ing amino acid.6,9 In silico analysis indicated that these are
likely benign variants that should be considered as passenger
mutations.
Discussion
Important lessons can be learned from tumors occurring in
hereditary settings.27 We describe a novel case of a patient
with a germline BRCA2 mutation and pancreatic ACC, and
review the literature on the prevalence of germline and
somatic BRCA1/2 alterations in ACC. Increasing evidence
suggests that at least a subgroup of ACCs develops on basis
of germline and somatic BRCA1/2 mutations, however their
role in the onset of pancreatic ACC is not yet well recognized.
Despite the rarity of ACC, hampering large studies, it is
crucial to establish the link between ACC and BRCA1/2 muta-
tions in view of the importance to recognize potentially her-
editary tumors and identify patients that may benefit from
targeted therapies.
Including the current case, a total of 10 ACC patients with
germline BRCA2 mutations have now been reported
(Table 2).7,17–21 Loss of the wild-type BRCA2 allele, observed inTa
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all cases with known zygosity,7,17 supports the causal relation
between BRCA2 germline mutation and the onset of ACC.
Moreover, literature review showed that somatic BRCA2 altera-
tions occur in about 12% of ACCs.6,7,9 Involvement of BRCA1 in
the onset of ACC remains elusive, although there are indications
of this association. So far, only two patients with pancreatic ACC
were reported to carry a germline BRCA1mutation.22–24 Somatic
BRCA1 alterations were observed in 4.3% of ACCs.3,6,7,9 However,
even more pancreatic ACCs may lack functional BRCA1/2. An
immunohistochemical analysis showed loss of BRCA2 expression
in 5 out of 11 ACCs (45%)7 and a recent whole-exome sequencing
(WES) study showed a mutational signature associated with
BRCA1/2 deficiency in 10 out of 22 ACCs (45%) despite the
absence of BRCA1/2mutations.3 Methylation of the BRCA1 pro-
moter was observed in 67% of ACCs in comparison to 28% of
PDACs and 50% of islet carcinomas,28 potentially indicating that
silencing of BRCA1 is a discriminative characteristic of ACC
contributing to its pathogenesis. Importantly, sequencing studies
revealed that about 7% of ACCs exhibited germline and up to
16% – somatic mutations in eitherBRCA1 or BRCA2 genes. Based
on abovementioned mechanisms, up to 22% of pancreatic ACCs
might exhibit BRCA1/2 deficiency (Table 4). In addition, loss of
one BRCA2 allele due to monosomy of chromosome 13 was
reported in two ACCs,29 and BRCA2 amplification – in one
ACC.30 Further research is needed to define whether these altera-
tions drive the pathogenesis of pancreatic ACC or occurmainly as
passengers due to extensive chromosomal instability observed in
this tumor type.
Of note, the actual prevalence of both germline and
somatic BRCA1/2 mutations in pancreatic ACC can be
under- or overestimated mainly due to the rarity of this
tumor type, lack of large-scale genomic analyses and possible
underrepresentation in literature. Patients with ACC and
germline BRCA1/2 alterations were often described in case
reports7,17–20,22,23 hindering the possibility to estimate real
portion of ACCs emerged due to BRCA1/2 germline muta-
tions. The heterogeneity observed between sequencing studies
is also remarkable: only one out of four studies detected
somatic BRCA1 mutations, and one WES study did not iden-
tify any BRCA1/2 mutation in 22 ACCs.3
Importantly, all cases of pancreatic ACC in patients with
germline7,17 and somatic7,26 BRCA2 mutations with known
zygosity demonstrated loss of the wild-type allele indicating
a driver role in the tumorigenesis of pancreatic ACC.
Moreover, among seven pancreatic cancer cases in the
Icelandic Cancer Registry harboring germline Icelandic foun-
der BRCA2999del5 mutation, LOH was observed in all three
ACCs (included in this review), but only in one out of four
PDACs.17 In the KrasG12D-driven murine model of pancreatic
cancer harboring a heterozygous pathogenic germline Brca2
mutation, acinar tumors developed in 5 out of 28 mice
(~18%) solely in the cohort with biallelic Brca2 inactivation.
Authors hypothesized that LOH of BRCA2 plays a defining
role in the triggering of pancreatic carcinogenesis towards
acinar lineage,17 however, further research is needed to eluci-
date the exact role of zygosity status and loss of wild-type
BRCA2 allele in the pathogenesis of ACC.
BRCA1 and 2 encode proteins that are crucial for DNA
repair by homologous recombination.31 Due to their pivotal
role in maintenance of genome integrity, BRCA1/2-deficient
tumors are particularly sensitive to therapies introducing
cross-linking and DNA damage, namely platinum-based che-
motherapies and PARP inhibitors.32 Furukawa et al. reported
complete remission in a patient with ACC and liver metastasis
and somatic BRCA2 mutation after treatment with
cisplatinum.7 Similarly, Ploquin et al. described a prolonged
14-year relapse-free survival of a male BRCA2 germline muta-
tion carrier with ACC and multiple liver and spleen
metastases.18 This patient was treated with the GEMOX regi-
men and demonstrated highest response rate to oxaliplatin
chemotherapy.18 A xenograft murine model PA-018, derived
from the ACC patient with somatic biallelic BRCA2
mutation,25 demonstrated the most pronounced and contin-
uous response to oxaliplatin.26 Several studies further reported
Table 3. Somatic BRCA1/2 mutations in pancreatic ACCs.
Reference, first author Year Type of ACC Sex Age at diagnosis (y) Gene CDS Mutation Protein Mutation reference
Furukawa7 2015 Pure ACC M 67 BRCA2 c.8297delCa p.T2766fs COSM4972287
Chmielecki9 2014 Pure ACC NS NS BRCA1 NS p.E1250fs COSM4603639
Pure ACC NS NS BRCA1 NS p.E23fs COSM1666624
Mixed ACC/NE NS NS BRCA1 NS splice NS
Mixed ACC/DA NS NS BRCA1 NS p.W1508* COSM4603640
Pure ACC NS NS BRCA2 NS p.R3128* COSM4603643
Pure ACC NS NS BRCA2 NS p.N1706fs COSM4603646
Pure ACC NS NS BRCA2 NS p.S1951fs COSM4603648
Pure ACC NS NS BRCA2 NS p.W563fs COSM4603651
Unknown ACCb NS NS BRCA2 NS p.S1982fs COSM166356
NS NS BRCA2 NS p.Q1987fs COSM4603645
Mixed ACC/NE, Unknown ACCc NS NS BRCA2 NS p.R645fs COSM4603647
Mixed ACC/NE NS NS BRCA2 NS p.N433fs COSM4603649
Unknown ACCc NS NS BRCA2 NS p.L659fs COSM4603650
Mixed ACC/DA/NE NS NS BRCA2 c.4535G>A p.R1512Hd COSM4603642
Jiao6 2014 Pure ACC M 66 BRCA2 c.1437C>G p.D479Ed COSM1734236
Hall,26 Armstrong25e 2016, 2011 Pure ACC M 61 BRCA2 c.1755_1759dela p.Lys585fs NS
ACC, acinar cell carcinoma; Y, year; M, male; F, female; NS, not stated; NE, neuroendocrine; DA, ductal.
aLoss of heterozygosity.
bUnknown ACC stands for ACC with incomplete histological analysis.
cSame unknown ACC.
dLikely benign variants.
eHall et al. (2016) developed a xenograft murine model derived from the liver metastasis of the patient with ACC described in paper by Armstrong et al. (2011),
therefore, data was collected from these two reports.
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increased sensitivity to platinum chemotherapeutics in other
BRCA1/2-deficient cancers,12,33,34 further emphasizing the
relevance of platinum-based therapies in patients with
BRCA1/2-related ACC. In our case, this advantageous effect
was observed as well.
PARP inhibitors exploit the phenomenon of “synthetic
lethality” when defects in certain genes are tolerated by
cells if occur separately, but are lethal in case of co-
occurrence.35 Clinical utility of PARP inhibitors is based
on the “two-hit” paradigm for tumor suppressor genes,
enabling them to selectively target BRCA1/2-deficient cells
while having no effect on BRCA1/2 wild-type or heterozy-
gous cells.17 Tumors of BRCA1/2 germline mutation carriers
in approximately 80% of cases experience inactivation of
wild-type allele by LOH.31 Moreover, a recent study by
Lowery et al. detected LOH of BRCA1 (60%) and BRCA2
(60%) in germline BRCA mutation carriers with exocrine
pancreatic malignancies.24 Since LOH of BRCA2 gene was
observed in all reported cases of ACC with known zygosity,
these tumors are expected to be sensitive to PARP inhibitors.
Notably, in a recent case report, Li et al. described a first case
of a patient with unresectable advanced pancreatic ACC and
a germline BRCA2 mutation that demonstrated a partial
response to the treatment with an oral PARP inhibitor
olaparib.21
Overall, up to 22% of pancreatic ACCs exhibit various
BRCA1/2 alterations (Table 4). This warrants genetic screen-
ing for the presence of BRCA1/2 deficiency in all patients
diagnosed with pancreatic ACC. Notably, genetic testing of
BRCA1/2 genes is widely utilized for patients with breast and
ovarian cancers, whereas the prevalence of these mutations
in unselected cohort of patients is reported to be only 3%
and 10%, respectively.36 Germline mutations in BRCA1/2
predispose to a range of cancers associated with Hereditary
Breast and Ovarian Cancer (HBOC) syndrome.37 Given that
pancreatic ACC can be a phenotypical expression of germ-
line BRCA1/2 mutations, screening of affected individuals
for their carrier status will provide important insights on
hereditary predisposition to HBOC also for their unaffected
relatives, which can undergo genetic screening to identify
their status and potentially benefit from preventive
measures.
To conclude, occurrence of ACCs in carriers of BRCA2
germline mutations strongly suggests that at least a part of
ACCs arise due to germline BRCA2 mutations. In addition,
somatic BRCA1/2 alterations and mutational signature asso-
ciated with BRCA1/2 deficiency are found in a significant
subset of sporadic ACCs. ACC patients should be screened
for the presence of BRCA1/2 deficiency, in order to apply
personalized therapy and to identify patients with hereditary
pancreatic cancer. Overall, this will promote early detection
and may improve survival of ACC patients.
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